Literature DB >> 6893298

Circulant anti-triiodothyronine antibodies in a patient with Graves' disease: effects on measurement of T3 with different RIA procedures.

J Rodriguez-Espinosa, J A Gomez-Gerique, J Ordoñez-Llanos, J Soldevila-Bosch, E Concustella-Bas.   

Abstract

High levels of triiodothyronine have been found in a patient with Graves' disease caused by circulating antibodies able to bind specifically with serum triiodothyronine. High values found were due to the interference of the endogenous antibody with the conventional techniques of radioimmunoassay used for the evaluation of the hormone. An analytical pattern to identify these antitriiodothyronine antibodies is described.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6893298     DOI： 10.1016/0009-8981(80)90170-9

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN： 0009-8981            Impact factor:   3.786


  5 in total

Review 1.  Circulating thyroid hormone autoantibodies.

Authors:  S Benvenga; F Trimarchi; J Robbins
Journal:  J Endocrinol Invest       Date:  1987-12       Impact factor: 4.256

2.  Deceptively high thyroid hormone levels in a neonate due to autoantibodies against thyroid hormones transferred from a mother with Graves' disease.

Authors:  N Momotani; K Ito; H Ohnishi; T Katsuki; M Yamamoto
Journal:  J Endocrinol Invest       Date:  1992-03       Impact factor: 4.256

3.  Antibody binding serum T3 in a patient with hepatocarcinoma.

Authors:  J Ordóñez-Llanos; J Rodríguez-Espinosa; J A Gómez-Gerique
Journal:  J Endocrinol Invest       Date:  1984-04       Impact factor: 4.256

4.  Circulating antitriiodothyronine autoantibodies in two euthyroid patients: apparent lack of interference in total T3 radioimmunoassay based on second antibody or solid phase separation techniques.

Authors:  P Beck-Peccoz; P B Romelli; G Faglia
Journal:  J Endocrinol Invest       Date:  1983-10       Impact factor: 4.256

5.  Thyroid hormone autoantibodies and their implications for free thyroid hormone measurement.

Authors:  S K Vyas; T J Wilkin
Journal:  J Endocrinol Invest       Date:  1994-01       Impact factor: 4.256
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.